Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Loans
  • Yacht Buyer
  • Finance
  • Stocks
  • Nyse
  • Banking
ncarol.com

Brazil awards ANVISA status to Biohit for its antigen and antibody Covid-19 test kits
ncarol.com/10072356

Trending...
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
CHARLOTTE, N.C., Sept. 2, 2020 /PRNewswire/ -- Biohit Healthcare's antibody and antigen tests for Covid-19 have been awarded ANVISA status, the official stamp of approval from Brazil's Ministry of Health. Biohit's Sars-CoV-2 IgM/IgG antibody test and SARS-CoV-2 Antigen quantitative assay kit are now included in the select group of Covid-19 tests of allowed manufacturers of goods in Brazil.

"Our Biohits test kits had already earned FDA's coveted EUA (Emergency Use Authorization) and now this great news from Brazil. Very exciting," says Dr. James Strader, CEO Bio Testing Supplies, the pandemic division of Avrio Genetics. "

Anvisa certification is granted only to companies that have been proven to maintain good manufacturing practices for health products so Biohit's approval by ANVISA means it meets the standards of Brazilian Class III vitro diagnostic products across the board. "It adds up to a blanket approval from the Brazilian government," says Strader.

"In their selection process, Brazil started with products already on the EUA authorization list and went from there, so selecting Biohit as only one of three companies to get the ANVISA é enorme…is huge," says Frederick M. Schaffer M.D., Board certified Immunologist, formerly an Associate Professor at the Medical University of South Carolina.

More on ncarol.com
  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
  • Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week

The Sars-Cov-2 Antigen test shows who has or does not have active Covid-19 while Biohit's Sars-CoV-2 IgM/IgG Antibody Test Kit, a rapid laminar flow assay (LFA) that typically delivers results within 15 minutes, identifies those who have already had the virus and have thus acquired antibodies. When evaluated by the FDA, this test was shown to have a very high IgM and IgG sensitivity as well as a very high specificity. "This is important as it shows who may have possible immunity and thus a potential green light to resume their daily life," explains Schaffer

With a population of close to 210 million—Brazil has about 2/3 the number of people in the U.S.—there is a lot of testing to be done. Biohit's ANVISA status will make it possible for these tests to play an important role in combating Covid-19 in this country.

"Fortunately we have several million Biohit test kits in the pipeline ready to be shipped by Bio Testing Supplies, a 'go to' company that also sells other diagnostic testing supplies including personal protective equipment (PPE)," adds Dr. Strader.

For more information and to order the Biohit test kit contact: biotestingsupplies.com

Media contact: [email protected]

SOURCE Bio Testing Supplies
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Wespor Business Launches AI Voice and Chat Agents to Help Triangle Small Businesses Capture Missed Leads
  • America's Boating Club Ushers in New Board at Change of Watch
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
  • PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
  • Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
  • From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
  • Cold. Clean. Anywhere. Meet FrostSkin
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
  • Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
  • Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Atlanta Magazine Names Dr. Rashad Richey One of Atlanta's Most Influential Leaders in 2026 as the FIFA World Cup Approaches
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
_catLbl0 _catLbl1

Popular on ncarol.com

  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring - 120
  • Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
  • Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?
  • CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos

Similar on ncarol.com

  • Tri-State Area Entrepreneur Launches K-Chris: A Premium Digital Destination for Luxury Fragrances
  • Why One American Manufacturer Builds BBQ Smokers to Aerospace Standards
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
  • How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
  • NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute